相关实验视频

Updated: Jan 8, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

低喉癌的放射治疗:对来自170多名患者的多机构数据的分析

Hideya Yamazaki¹, Gen Suzuki¹, Aibe Norihiro¹

¹Radiology, Kyoto Prefectural University of Medicine, Kyoto, JPN.

|December 18, 2025

概括

放射治疗 (RT) 有效地治疗下癌 (HPC),强度调节RT (IMRT) 显示与3D符合RT (3DCRT) 类似的结果. 这两种方法都提供了有利的生存率和控制率,具有可接受的毒性.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

低癌 (HPC) 是一种具有挑战性的癌症.
放射治疗 (RT) 是HPC的主要治疗方式.
在RT技术的进步,如强度调节放射治疗 (IMRT),旨在改善结果.

研究的目的:

为了评估绝对辐射疗法对下喉癌的疗效.
为了比较传统的3D符合辐射疗法 (3DCRT) 和强度调节辐射疗法 (IMRT) 之间的结果.
评估RT对整体存活率,局部控制,局部区域控制,无进展存活率和毒性的影响.

主要方法:

对171名患有I-IV期HPC的患者进行了回顾性分析,这些患者接受了最终RT治疗.
在2008年至2024年期间,患者接受3DCRT (n=87) 或IMRT (n=84) 治疗.
主要终点:整体存活率 (OS);次要终点:局部控制 (LC),局部区域控制 (LRC),无进展存活率 (PFS) 和毒性.

主要成果:

随访时间中位数为32个月.
两年经营率:83.9%;五年经营率:69.0%.
两年LC: 81.1% (5年: 74.1%); LRC: 78.1% (5年: 71.3%); PFS: 64.3% (5年: 52.3%). 在这两年里,LRC的增长率是78.1% (5年: 71.3%); PFS: 64.3% (5年: 52.3%).
先进的T类预测LC/LRC差;N类预测OS (HR=1.7).
晚期等级≥3毒性发生在2.8%的患者中.
从3DCRT过渡到IMRT并没有显著改变瘤控制或毒性.

结论:

确定的放射治疗给HPC患者带来了有利的生存率和控制率.
对HPC的RT显示了可接受的毒性概况.
在治疗HPC时,IMRT的疗效和安全性与3DCRT相美.

关键词:

头部和部的癌症头部和部的癌症化学疗法或放射治疗鼻下的癌症是一种癌症.强度调节的放射疗法强度调节的放射治疗辐射疗法辐射疗法

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...